The best life sciences deals are found, not marketed.
Tulevik combines deep sector intelligence with principal-led M&A advisory — helping investors and operators identify opportunities earlier and execute with conviction.
advising life sciences investors and operators
combined principal transaction experience
transactions directed by our principals
North America, Europe, Latin America, Asia
Four decisions that determine the outcome
Tulevik helps investors, strategics, and innovators answer the questions that shape every life sciences transaction — with clarity, conviction, and evidence.
Where to play?
Identify the most attractive markets, technologies, and opportunity spaces across the life sciences.
What to pursue?
Prioritise the targets, partnerships, and investments that actually create strategic value.
When to act?
Read market readiness and transaction conditions, and move at the right moment.
How to win?
Execute transactions and market entry with confidence and strategic clarity.
From opportunity to execution
Tulevik supports the full strategic decision lifecycle — finding the opportunity, transacting on it, and scaling what follows.
Deal intelligence
Capabilities
Outcomes
Curated M&A advisory
Capabilities
Outcomes
Insight-driven market entry
Capabilities
Outcomes
Brought in mid-process
Site capability, capacity, compliance exposure, remediation cost
Approval pathway risk, inspection history, filing portfolio review
Network assessment, single-source exposure, cold chain
Asset comparables, contract economics, utilisation analysis
Demand modelling, competitive benchmarking, primary research
Who you'll work with
Tulevik is led by two principals. Every engagement is run by one of them.
Every engagement is principal-led and supported by analysts and specialist consultants selected for the mandate.
Why clients bring us in
Unique intelligence, deep sector expertise, and trusted networks that uncover opportunities others miss.
Two decades advising investors and operators across the pharmaceutical value chain, with manufacturing evaluated first-hand across biologics, aseptic fill-finish, vaccines, advanced therapies, and APIs.
A trusted network of executives, investors, and operators that surfaces opportunities and insight beyond traditional advisory channels.
Our proprietary methodology, combining asset-level manufacturing intelligence with transaction analytics and two decades of direct relationships across the sector.
Tulevik doesn't stop at analysis. We stay in the room from opportunity discovery through transaction execution and post-deal expansion.
Our areas of expertise
Deep expertise across the life sciences ecosystem. Headquartered in Victoria, British Columbia, with engagements across North America, Europe, and Latin America.
Industries we serve
Value chain coverage
Transaction types
Selected experience
Representative engagements led by Tulevik’s principals. Client and counterparty names withheld by agreement.
Retained to find a large-scale liquid manufacturing site. Screened 207 FDA-registered liquid and topical facilities across the US and Canada against a defined technical specification, prioritised 68, shortlisted 12 through confidential outreach and site visits, and qualified four actionable targets to a single recommendation. 207 screened, 12 site-visited, 1 recommended.
Evaluated a universe of 700+ companies to define acquisition criteria, test platform theses, and build a prioritised target list for a buy-and-build strategy. 700+ companies screened to a ranked platform thesis.
Retained to identify sterile manufacturing capability. Identified 231 aseptic operations across the US and Canada, filtered to 22 prioritised sites against client technical criteria, qualified six actionable targets, and benchmarked 17 comparable aseptic facility transactions. 231 operations screened, 6 actionable targets, transaction completed.
Ran a structured sell-side process for a manufacturing asset, engaging a buyer pool of 300+ and profiling 50+ high-priority prospects to build competitive tension deliberately. 300+ buyers engaged, 50+ prospects profiled.
Assessed the US GMP cold storage market across four temperature regimes — refrigerated, frozen, ultra-low, and cryogenic — sizing demand, mapping national and regional providers, profiling end-user requirements, and modelling revenue. Delivered a ranked entry recommendation with configuration and redundancy guidance.
Engaged mid-process to deliver fast-turnaround market intelligence and site deep dives, drawing on subject-matter experts to surface red flags and upside ahead of a committee decision. Two-week turnaround inside a live process.
Who we work with
Tulevik supports investors, strategics, and innovators across the global life sciences ecosystem.
Private equity and growth investors seeking proprietary deal flow, platform strategies, and transaction support.
Companies and sponsors pursuing acquisitions, partnerships, and growth in complex manufacturing and services markets.
Organisations evaluating acquisitions, partnerships, and strategic expansion.
Banks, advisory firms, and corporate development groups needing life sciences depth inside a live transaction.
Innovators navigating commercialisation strategy, partnerships, and market entry.